A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

Ascendis Pharma Endocrinology Division A/S

Summary

The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.

Eligibility

Age range: 1–18 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Paediatric patients with GHD who are on treatment with lonapegsomatropin * Patients being clinically managed in Europe or the USA * Appropriate written informed consent/assent as applicable for the age of the patient * Patients willing to comply with follow-up requirements of the study Exclusion Criteria: * Patients participating in any interventional clinical trial for short stature * Patients being treated with a GH or IGF-1 therapy, other than lonapegsomatropin, at enrollment * Patients for whom treatment with lonapegsomatropin is contraindicated * Patients with clo…

Locations (27)

Ascendis Investigational Site
Phoenix, Arizona
Ascendis Investigational Site
Orange, California
Ascendis Investigational Site
Sacramento, California
Ascendis Investigational Site
San Francisco, California
Ascendis Pharma Investigational Site
Centennial, Colorado
Ascendis Investigational Site
Washington D.C., District of Columbia

Summary

Eligibility

Interventions

Locations (27)